Regulatory

CBD is an established product that is paving the way for other hemp-derived cannabinoids. However, regulation remains a big if for the category.

The U.S. Food and Drug Administration has reached the conclusion that “a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”

FDA warning letters in 2022 remind cardiovascular product companies about what they should and shouldn’t do in 2023.

FermentIQ is designed to improve the sensory, functional, and nutritional attributes of plant protein, the company says.

Astrion is a combination of Centella asiatica and Astragalus membranaceus that the company says has been clinically shown to support skin health.

David Murray, the director of the Office of Disease Prevention at the National Institutes of Health, is currently serving as the acting director of the Office of Dietary Supplements (ODS) until a new, permanent ODS director is selected.

Nutritional Outlook’s Editorial Advisory Board shares its predictions and tips for success in 2023.

FDA’s final guidance outlines how importers should comply with FSVP requirements, including those for importers of dietary supplements.

New York Governor Kathy Hochul has vetoed Assembly Bill 431-C, which would restrict minors from purchasing weight management and muscle building dietary supplements without a prescription.

The listing for galactooligosaccharides in the European Union’s list of Novel Foods now mentions Foods for Special Medical Purposes (FSMPs).

The 2023 Omnibus Appropriations bill, a $1.7 trillion government funding package was released early on Tuesday, December 20, 2022 without a mandatory product listing provision.

The Council for Responsible Nutrition has issued a statement responding to claims made by the Natural Products Association on social media and other platforms related to mandatory product listing legislation, CRN’s support of MPL, and Senator Richard Durbin’s (D-IL) relationship to the dietary supplement industry.

With the bill awaiting Governor Hochul's signature, NPA sends request for veto. Similar NJ bill was up for a vote in the Assembly, but was pulled following concerns raised by NJ Department of Health.

Leading industry attorneys dig into the complexities of FDA’s announcement.

Given the interest in reviewing and considering amendments to several provisions of FD&C that would affect dietary supplements, AHPA believes strongly that these amendments should be addressed collectively in the 118th Congress. That way, stakeholders can fully engage with Congress.

Sebastian Krawiec, editor of Nutritional Outlook, talked to Daniel Fabricant, president and CEO of the Natural Products Association about a recent Marist Poll sponsored by the organization, and regulatory priorities.

Sebastian Krawiec, editor of Nutritional Outlook talks to Steve Mister, president and CEO of the Council for Responsible Nutrition about the organization’s recent consumer survey and its regulatory priorities before the close of the legislative session and beyond.

PeptiStrong contains natural peptides derived from fava bean.

The approval was given after a multiyear review by ANVISA of Ahiflower’s safety and efficacy substantiation.

Royal DSM’s human-identical milk oligosaccharide (HMO) GlyCare 2’-fucosyllactose (2FL) was approved in Canada for use in infant formula and nutritional supplements for toddlers aged one to three years of age.

The U.S. Food and Drug Administration has completed its first pre-market consultation for human food made from animal cell cultures with UPSIDE Foods.

Supplement companies are branching out into novel delivery formats, but their number-one goal should still be to stick within the bounds of supplement regulations.

The U.S. Food and Drug Administration has sent warning letters to five companies for selling food and beverage products that contain cannabidiol (CBD).

On November 17, the agency sent warning letters to Essential Elements, Calroy Health Sciences, Iwi, BergaMet North America, Healthy Trends Worldwide, Chambers’ Apothecary, and Anabolic Laboratories.

The American Herbal Products Association held its Congress on Regulatory Priorities in the Natural Products Market on Tuesday, November 15, 2022.

The U.S. Food and Drug Administration (FDA) has determined that beta-nicotinamide mononucleotide (NMN) is not a dietary ingredient citing the drug preclusion clause of the Food Drug and Cosmetic Act (FD&C).

The Natural Products Association provided testimony on November 14, 2022, in opposition to A 3512 during the New Jersey Assembly Health Committee.

Recent negative headlines cast melatonin in an unfavorable light. Is there any justification for the bad press?